Overview / Abstract: |
In this CME/NCPD activity, D. Ross Camidge, MD, PhD, of the University of Colorado, and Beth Sandy, MSN, CRNP, OCN®, of the University of Pennsylvania, discuss novel treatments for advanced KRAS mutation-positive NSCLC and how to manage adverse events associated with small molecule inhibitors. Start now! An estimated 228,820 new cases of lung cancer are reported in the United States annually, and 135,720 people die of the disease (ACS, 2020). Approximately 84% of cases are classified as non-small cell. Most patients are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management (ACS, 2020). Although 70% of patients receiving first-line classical doublet chemotherapy demonstrate clinical benefit, most develop progressive disease within 5 months of their final cycle (Lazzari et al, 2017). Recently, the use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers to further refine selection of novel therapies has improved outcomes for some patients. Unfortunately, the 5-year survival rate for patients with NSCLC remains a dismal 24%, indicating a need for continued research on more effective approaches to tumor control (ACS, 2020; NCI, 2019). LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: Discuss the therapeutic implications of KRAS G12 mutation status in advanced NSCLC |
Expiration |
Mar 25, 2022 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Podcast, Webinar / Webcast / Video |
Credits / Hours |
0.75 CME | 0.75 NCPD | MOC | ILNA |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
D. Ross Camidge, MD, PhD Beth Sandy, MSN, CRNP, OCN® |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Amgen. |
Keywords / Search Terms |
i3 Health i3 Health i3 Health i3 Health, NSCLC, non-small cell lung cancer, KRAS Mutation–Positive NSCLC, NSCLC online CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME Free CE CME Free CE CME Free CE CME Free CE CME |